Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

  • Allergan has returned development rights to Heptares for its muscarinic M1 agonist designed to treat Lewy body-based dementia.
  • In a secret deal, Oxford BioDynamics has a new “major US pharma” partner.
  • French spinout Dynacure licensed a drug for centronuclear myopathy from Ionis.

  • Novartis is looking for EMA approval of Kymriah, its recently FDA-approved CAR-T therapy.
  • Nordic Nanovector amended its protocol to continue with its Phase II trial for its mAb Betalutin in the UK.
  • ReNeuron also received approval to move its retinal disease candidate forward into Phase II.
  • Adaptimmune reported early-stage positive results for its SPEAR T-Cell therapy.

Images from Marco Diaz Segura, FACTORYPIC, Tilo G

SaveSave

SaveSave

This awesome article More News! Novartis is going for EMA Approval for CAR-T Therapy appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉



Source link